Hope for pancreatic cancer prevention: old drug, new trial
NCT ID NCT04207944
First seen Jun 09, 2026 · Last updated Jun 13, 2026 · Updated 2 times
Summary
This study tests whether the anti-inflammatory drug sulindac can prevent high-risk pancreatic cysts (IPMNs) from progressing to pancreatic cancer. About 100 adults with these cysts will receive either sulindac or a placebo for up to 3 years, alongside standard monitoring. The goal is to see if the drug reduces cyst growth, new cysts, or cancer development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPMN, PANCREATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering
New York, New York, 10021, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.